HRAS and melanoma: Altogether, these results suggest that targeting the expression of the HRAS oncogene to a population of cells that express the kita gene is able to induce melanoma development with high efficiency (i.e. without the need for additional mutations that inactivate tumor suppressors) and in a relatively short time (2–4 weeks).